Funding Opportunities Tracking
| FOA No. | Title | Org | Release/Open Dates | Exp. Date | Activity Code(s) | No. Awards | Amount | Comments |
|---|---|---|---|---|---|---|---|---|
| NOT-HS-20-001 | Notice of Intent to Publish Funding Opportunity Announcement to Improve the Management of Opioids and Opioid Use Disorder in Older Adults | AHRQ | Release Date: 10/25/2019 Open Date: | |||||
| FOR-FD-20-008 | FOR-FD-20-008 | Food and Drug Administration | Release Date: Open Date: 03/06/2020 | Forecasted | ||||
| HHS-2020-IHS-COIPP-0001 | Community Opioid Intervention Pilot Project | Department of Health and Human Services | Release Date: 02/14/2020 Open Date: | Forecasted | ||||
| HRSA-20-014 | Opioid-Impacted Family Support Program | Release Date: Open Date: | 19 | |||||
| NOT-DA-20-062 | Notice of Clarification to PAR-19-064, "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)" | NIDA | Release Date: 06/11/2020 Open Date: | The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse is adding a priority area focused on policy-relevant research and researcher-practitioner partnerships to PAR-19-064, Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional). | ||||
| HRSA-21-088 | Rural Communities Opioid Response Program – Implementation | HRSA | Release Date: 09/04/2020 Open Date: | 78 | 78M total program | |||
| HRSA-21-091 | Rural Communities Opioid Response Program – Psychostimulant Support | HRSA | Release Date: 01/06/2021 Open Date: | 15 | $7.5M Total program | Forecasted | ||
| NOT-DA-20-071 | Rural Communities Opioid Response Program – Psychostimulant Support | HRSA | Release Date: 11/01/2020 Open Date: | 3 | Notice The National Institute on Health (NIH) intends to publish two Funding Opportunity Announcements (FOA) to solicit applications to build a network of researchers to develop sustainable evidence-based interventions to effectively treat non-cancer chronic pain (CP) and opioid use disorder (OUD). This network will be part of the of the NIH’s Helping to End Addiction Long-term (HEAL)SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management. | |||
| NOT-TR-20-025 | NCATS Announces Plans to Publish the ASPIRE 2020 Reduction-to-Practice Challenge Prize Competition | NCATS | Release Date: 08/26/2020 Open Date: | In this Reduction-to-Practice Challenge, the second phase of the initiative, NCATS aims to build upon the designs from the Design Challenges and reward the development of a working prototype of a comprehensive integrated platform, culminating in the development of better, more effective and non-addictive analgesics. It is anticipated that this Challenge would require large, multi-expert teams. These teams may be assembled from the innovators from the 2018 Design Challenge areas and others who did not participate in the 2018 Design Challenges. This Notice alerts the scientific community that NCATS intends to hold a three-stage prize open competition for the NCATS ASPIRE Reduction-to-Practice Challenge, the stages are 1) planning, 2) prototype development and milestones delivery, and 3) prototype delivery and validation and testing. It is anticipated that the announcement will be published in September 2020, with the submission window for Stage 1 planning solutions from late November through the end of February 2021. | ||||
| SP-19-006 | Drug-Free Communities (DFC) Support Program-Competing Continuation | DFC | Release Date: Open Date: | |||||
| SP-19-005 | Drug-Free Communities (DFC) Support Program-New | DFC | Release Date: Open Date: | |||||
| RFA-DA-20-019 | Exploiting In Vivo Precision Pharmacology Techniques to Understand Opioid Receptor Signaling in Specific Circuits, Cell Types, and Subcellular Compartments (R61/R33 - Clinical Trial Not Allowed) | NIDA | Release Date: 05/30/2019 Open Date: 09/17/2019 | R61/R33 | 5 | Up to $300K | ||
| PA-FPR-19-001 | FORECASTED: Availability of funds for Title X Family Planning– Innovations in Family Planning Clinical Service Delivery and Studies to Address Opportunities and Barriers for Linking Family Planning Services and Substance Use Disorder Screening and Treatment | DHHS/OASH | Release Date: Open Date: | 10 | $400K | |||
| HHS-2019-ACF-ACYF-CU-1568 | Regional Partnership Grants to Improve Well-Being and Permanency Outcomes for Children and Families Affected by Opioids and Other Substance Abuse | DHHS | Release Date: Open Date: | 7 | Up to $2.65M | |||
| BJA-2019-15111 | BJA FY 19 Comprehensive Opioid Abuse Site-based Program | DOJ | Release Date: 04/05/2019 Open Date: | 150 | Up to $5M | |||
| BAA-DAIT-75N93019R00009 | Development of Vaccines for the Treatment of Opioid Use Disorder | NIAID | Release Date: 03/05/2019 Open Date: | $2-3M/year | ||||
| NOT-DA-19-048 | Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and Addiction | Release Date: Open Date: | ||||||
| NOT-DA-19-041 | Notice of Special Interest (NOSI): The Application of Big Data Analytics to Drug Abuse Research | Release Date: Open Date: | ||||||
| NOT-DA-19-38 | Notice of Special Interest (NOSI): Gene-Environment Interplay in Substance Use Disorders (R01, R21) | Release Date: Open Date: | ||||||
| NOT-DA-19-037 | Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03) | Release Date: Open Date: | ||||||
| NOT-AA-19-020 | Notice of NIAAA Data-Sharing Policy for Human Subjects Grants Research Funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) [2nd Revision] | NIAA | Release Date: 07/31/2019 Open Date: | Several FOA's affected by this notice | ||||
| NOT-DA-19-035 | Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional) | NIDA | Release Date: Open Date: | |||||
| PA-18-078 | Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional) | NIDA | Release Date: 11/03/2017 Open Date: 01/17/2018 | 01/08/2020 | R21 | $275K for 2 years | ||
| PA-17-120 | Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01) | NIDA | Release Date: 01/10/2017 Open Date: 01/10/2017 | 01/08/2020 | R01 | Not limited | ||
| FOA-ETA-20-01 | The Support to Communities: Fostering Opioid Recovery Through Workforce Development | NIDA | Release Date: 10/31/2019 Open Date: | 01/10/2020 | Up to $5,000,000 | |||
| RFA-DA-20-025 | Step Up for Substance Use Disorders (SUD): A Drug Target Initiative for Scientists Engaged in Fundamental Research (U18 - Clinical Trial Not Allowed) | NIDA | Release Date: 11/14/2019 Open Date: 01/13/2020 | 02/14/2020 | U18 | Estimate of 50 awards | $150,000 directs/year | |
| RFA-DA-19-002 | Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional) | NIDA | Release Date: 12/14/2017 Open Date: 01/25/2018 | 02/23/2020 | UG3/UH3 | 3 to 4 | Total $10M/Fiscal year | |
| BJA-2020-17754 | BJA FY 20 Harold Rogers Prescription Drug Monitoring Program (PDMP) | Department of Justice Bureau of Justice Assistance | Release Date: 03/06/2020 Open Date: | 03/05/2020 | 14 | $2,000,000 | ||
| RFA-NS-18-046 | Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional) | NINDS | Release Date: 09/19/2018 Open Date: 10/27/2018 | 03/13/2020 | R61/R33 | 8 to 10 | Not limited | |
| RFA-NS-18-041 | Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional) | NINDS | Release Date: 08/02/2018 Open Date: 10/27/2018 | 03/13/2020 | R61/R33 | 8 to 10 | Not limited | |
| TI-20-006 | SAMHSA | Release Date: 01/17/2020 Open Date: 01/17/2020 | 03/17/2020 | 2 | $850,000/year | |||
| RFA-HL-20-031 | HEAL Initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development (R61/R33 - Clinical Trial Not Allowed) Department of Health and Human Services | NIH | Release Date: 01/24/2020 Open Date: 01/24/2020 | 03/24/2020 | R61/R33 | NHLBI intends to commit total costs of up to $7,000,000 in FY2020-2021 to fund up to 10Phase I (R61) awards. NHLBI intends to commit total costs of up to $3,000,000 per year in FY2022-2024 to fund up to 5 Phase II (R33) awards. | ||
| TI-20-007 | Services Grant Program for Residential Treatment for Pregnant and Postpartum Women | SAMHSA | Release Date: 01/30/2020 Open Date: 01/30/2020 | 03/30/2020 | 3 | $1,800,000 | ||
| RFA-AT-20-004 | HEAL Initiative: Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) (UG3/UH3, Clinical Trials Optional) | NIH | Release Date: 01/23/2020 Open Date: 02/29/2020 | 03/31/2020 | UG3/UH3 | 1-2 | The application budget for the UG3 phase is limited to $500,000/year in direct costs. Costs for each year of the UH3 phase are limited to $1 million/year in direct costs. | |
| NOT-DA-20-044 | Tufts CTSI Launches COVID-19 Pilot Studies Program | Tufts University | Release Date: Open Date: | 04/13/2020 | $700,000 | The Tufts CTSI COVID-19 Pilot Studies Program seeks proposals for innovative, high-impact, translational science projects from the basic, clinical, and/or applied sciences to address the urgent need for research on COVID-19. We anticipate funding two awards at $25,000/each. Proposed approaches could include studies that: This is a fast-track funding opportunity: the deadline for applications is Monday, April 13. PLEASE NOTE: Applicants must adhere to all home institutional PRIOR APPROVAL requirements regarding COVID-19 research as it applies to data requests, biorepository/samples, clinical trials, registries, etc. Questions? Email pilots@tuftsctsi.org. | ||
| HRSA-20-106 | Rural Communities Opioid Response Program – Neonatal Abstinence Syndrome (RCORP-NAS) | Department of Health and Human Services Health Resources and Services Administration | Release Date: 02/06/2020 Open Date: 02/06/2020 | 04/14/2020 | 30 | Estimated Total Program Funding: | ||
| TI-20-010 | State Pilot Grant Program for Treatment for Pregnant and Postpartum Women | SAMHSA | Release Date: 02/19/2020 Open Date: | 04/20/2020 | 5 | Up to $900,000 | ||
| BJA-2020-17106 | BJA FY 20 Improving Reentry for Adults with Substance Use Disorders Program | Department of Justice Bureau of Justice Assistance | Release Date: 02/26/2020 Open Date: | 04/27/2020 | 14 | $900,000 ceiling | ||
| TI-20-011 | 2020 Tribal Opioid Response grants | SAMHSA | Release Date: 03/03/2020 Open Date: 03/03/2020 | 05/04/2020 | 200 | $1,800,000 | ||
| TI-20-009 | 2020 Rural Opioid Technical Assistance Grants | SAMHSA | Release Date: 03/09/2020 Open Date: 03/09/2020 | 05/08/2020 | 5 | $550,000 | The purpose of this program is to develop and disseminate training and technical assistance for rural communities on addressing opioid issues affecting these communities. It is expected that recipients will facilitate the identification of model programs, develop and update materials related to the prevention, treatment, and recovery activities for opioid use disorder (OUD), and ensure that high-quality training is provided. | |
| PA-18-079 | Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R21 Clinical Trial Optional) | NIDA/NIA | Release Date: 11/03/2017 Open Date: 01/17/2018 | 05/08/2020 | R21 | $275K for 2 years | ||
| PA-18-061 | Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R01 Clinical Trial Optional) | NIDA/NIA | Release Date: 11/03/2017 Open Date: 01/06/2018 | 05/08/2020 | R01 | Not limited | ||
| PA-17-157 | Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R21) | NIDA | Release Date: 02/08/2017 Open Date: 05/16/2017 | 05/08/2020 | R21 | $275K for 2 years | ||
| PA-17-155 | Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R01) | NIDA | Release Date: 02/08/2017 Open Date: 05/05/2017 | 05/08/2020 | R01 | Not limited | ||
| PA-17-134 | Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R03) | NIAAA | Release Date: 01/25/2017 Open Date: 05/16/2017 | 05/08/2020 | R03 | $50K/year | ||
| PA-17-132 | Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R21) | NIAAA | Release Date: 01/25/2017 Open Date: 05/16/2017 | 05/08/2020 | R21 | $275K for 2 years | ||
| RFA-FD-20-031 | Incorporating cost effectiveness & societal outcomes into FDA opioids model (U01) Clinical Trials Not Allowed | FDA | Release Date: 03/13/2020 Open Date: 03/16/2020 | 05/19/2020 | U01 | The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support. | 1,000,000 | |
| BJA-2020-17023 | BJA FY 20 Comprehensive Opioid, Stimulant, and Substance Abuse Site-based Program (COSSAP) | Department of Justice Bureau of Justice Assistance | Release Date: 02/21/2020 Open Date: 02/21/2020 | 05/21/2020 | 120 | $6,000,000 | ||
| HRSA-20-031 | Rural Communities Opiod Response Program - Implementation | HRSA | Release Date: 05/13/2019 Open Date: | 05/26/2020 | 79 | $79M program | ||
| I-20-013 | Treatment, Recovery, and Workforce Support Grant | SAMHSA | Release Date: 03/31/2020 Open Date: | 06/01/2020 | 8 | $500,000 | ||
| NOT-TR-20-008 | Notice of Special Interest for HEAL Initiative: Request for Administrative Supplements to Existing Grants for Identification and Validation of New Pain and Opioid Use Disorder Targets within the Understudied Druggable Genome | NCATS, NIDCR, NIDA, NINDS, NCCIH | Release Date: 03/09/2020 Open Date: 03/17/2020 | 06/02/2020 | Not to exceed $99,999 | This Notice is part of the NIH Helping to End Addiction Long-Term (HEAL) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. NCATS and other participating institutes and Centers (ICs) are inviting investigators with relevant active research project grants and cooperative agreements to submit administrative supplements, according to PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional), for funded projects to identify and validate new pain and opioid use disorder (OUD) targets from within the understudied Druggable Genome. | ||
| CDC-RFA-CE20-2002 | Drug-Free Communities (DFC) Support Program-New | CDC | Release Date: 02/18/2020 Open Date: | 06/08/2020 | 200 | $125,000 | ||
| CDC-RFA-CE20-2002 | Drug-Free Communities (DFC) Support Program-New Department of Health and Human Services Centers for Disease Control - NCIPC | CDC | Release Date: 02/18/2020 Open Date: 02/18/2020 | 06/08/2020 | 200 | $125,000 | ||
| NOT-NS-20-023 | Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-18-906 Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) | HEAL | Release Date: 03/03/2020 Open Date: 04/15/2020 | 06/30/2020 | Contingent upon appropriations | $50.000 | Related Announcements | |
| NOT-DA-20-044 | Notice of Intent to Publish a Funding Opportunity Announcement for NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional) | DHHS/NIH | Release Date: 04/06/2020 Open Date: 05/01/2020 | 07/13/2020 | $700,000 | |||
| RFA-DA-18-020 | NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional) | NIDA | Release Date: 12/06/2018 Open Date: 06/25/2019 | 07/26/2020 | UG3/UH3 | Up to 2/year | Total $2M FY2019 | |
| NOT-NS-20-044 | Clinical Research in Pain Management | HEAL | Release Date: 06/01/2020 Open Date: 05/15/2020 | 07/31/2020 | DP1 | Contingent upon appropriations | $50.000 | Related Announcements |
| Strengthening Access to Care for Opioid Use Disorder Patients During the COVID-19 National Public Health Emergency: Recovery Support Services | FORE | Release Date: 05/22/2020 Open Date: 05/22/2020 | 07/31/2020 | Foundation | Contingent upon NIH appropriations | $25K-$75K | https://forefdn.org/wp-content/uploads/2020/05/COVID19_RFP_FINAL_5-22-2020.pdf | |
| Systems for Action: Supplemental Research on COVID-19 Response and Recovery | Robert Wood Johnson Foundation | Release Date: Open Date: | 08/05/2020 | Foundation | 5 | Up to $100K/year | ||
| RFA-DA-21-001 | Reducing Stigma Related to Drug Use in Human Service Settings (R34 Clinical Trial Required) Department of Health and Human Services National Institutes of Health | DHHS/NIH | Release Date: 04/09/2020 Open Date: | 08/11/2020 | R34 | 2 | $450,000 | |
| PAR-20-224 | Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional) | Release Date: 06/01/2020 Open Date: 07/13/2020 | 08/16/2020 | DP2 | $375,000 | |||
| RFA-DA-18-022 | Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01 Clinical Trial Optional) | NIDA | Release Date: 03/14/2018 Open Date: 07/22/2018 | 08/22/2020 | R01 | 3 to 4 | ||
| PAR-18-746 | NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) | NIDA | Release Date: 04/06/2018 Open Date: 05/11/2018 | 08/29/2020 | K12 | $500K Direct costs/year | ||
| PAS-18-625 | Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional) | NIDA | Release Date: 02/02/2018 Open Date: 05/16/2018 | 09/08/2020 | R21 | 3 to 5 | Total $2M for FY2019 | |
| PAS-18-625 | Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional) | NIDA | Release Date: 02/02/2018 Open Date: 05/16/2018 | 09/08/2020 | R21 | 3 to 5 | $275K total project | |
| EDSUSS-2020 | Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional) | The Office of National Drug Control Policy (ONDCP) | Release Date: 08/14/2020 Open Date: 08/14/2020 | 09/14/2020 | $300K | This project seeks to further refine and geographically expand a methodology for obtaining drug early warning indicators through broader testing of urine samples that were previously collected and tested as part of an existing drug test protocol. This method was initially developed using local criminal justice populations – including persons in pre-trial or lock-up, parolees or probationers, and drug court participants. Similar methodology is promising for use in other venues, such as in trauma units and emergency departments, where biological samples are often collected from patients. Before the specimens are discarded, the project will re-test them for an expanded panel of drugs, including synthetic cannabinoids, to determine what old and new illicit drugs are detected or missed by conventional testing protocols, and how the drug patterns might vary by subpopulation and geography. Bypassing the expense of collecting the original specimens and re-using those that have already been tested with known results yields a relatively inexpensive and timely picture of emerging drugs in a given subpopulation and locality. ONDCP is seeking to apply this testing methodology to Emergency Department populations in locations throughout the United States. | ||
| PAR-20-182 | Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed) | NIDA | Release Date: 05/04/2020 Open Date: 09/30/2020 | 10/31/2020 | R01 | 1-3 | Less than $1M/year for upt ot 5 years | |
| PAR-20-241 | Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed) | NIDA | Release Date: 06/24/2020 Open Date: 09/30/2020 | 10/31/2020 | R01 | 1-3 | $1M | |
| RFA-DA-21-024 | PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional) | NIDA/NIAID | Release Date: 06/29/2020 Open Date: 10/12/2020 | 11/13/2020 | R01 | 2-3 | $2.5M over 5 years | |
| RFA-DA-21-024 | PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional) | NIDA, NIAID | Release Date: 06/29/2020 Open Date: 10/12/2020 | 11/13/2020 | R01 | 2-3 | Not limited | |
| PAR-18-747 | Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R01 Clinical Trial Optional) | NIMHD | Release Date: 04/10/2018 Open Date: 05/15/2018 | 11/14/2020 | R01 | Not limited | ||
| PAR-18-745 | Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R21 Clinical Trial Optional) | NIMHD | Release Date: 04/10/2018 Open Date: 05/15/2018 | 11/14/2020 | R21 | $275K for 2 years | ||
| PAR-20-237 | Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional) | Release Date: 06/17/2020 Open Date: 07/28/2020 | 12/02/2020 | R01 | Contingent upon NIH appropriations | $500,000/year | ||
| PA-18-591 | Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) | NIH | Release Date: 01/25/2018 Open Date: 01/25/2018 | 01/26/2021 | ||||
| RFA-NS-19-018 | HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional) | NINDS | Release Date: 12/10/2018 Open Date: 12/10/2018 | 02/23/2021 | UH3 | 3 to 4 | Total $3M | |
| RFA-NS-19-017 | HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional) | NINDS | Release Date: 12/10/2018 Open Date: 12/10/2018 | 02/23/2021 | U44 | 4 to 8 | Not to exceed $1M/year in Phase 1 | |
| RFA-NS-19-016 | HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional) | NINDS | Release Date: 12/10/2018 Open Date: 12/09/2018 | 02/23/2021 | UG3/UH3 | 3 to 6 | Total $4M | |
| RFA-EB-18-003 | HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed) | NIBIB | Release Date: 12/10/2018 Open Date: 01/08/2019 | 02/23/2021 | U18 | 5 to 10 | Not to exceed $500K | |
| NOT-MD-20-019 | Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities | NIMHD, NIA, NIMH | Release Date: 04/10/2020 Open Date: 05/01/2020 | 05/01/2021 | P20 | 125,000 | ||
| PAR-19-159 | Bioengineering Research Grants (BRG) (R01 Clinical Trial Required) | Multi | Release Date: 01/08/2019 Open Date: 01/08/2019 | 05/08/2021 | R01 | Not limited | Translational group | |
| PAR-18-362 | Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional) | NIDA and NIAAA | Release Date: 09/09/2019 Open Date: 09/05/2019 | 09/08/2021 | R01 | Contingent upon appropriations | Up to $499,999 directs/year | Up to 5 year project period Related Notices |
| RFA-DA-19-020 | HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R41/R42 - Clinical Trial Optional) | NIDA | Release Date: 12/10/2018 Open Date: 01/10/2019 | 09/09/2021 | R41/R42 | 3 to 10 | Total $3M FY2019 | |
| RFA-DA-19-019 | HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R43/R44 - Clinical Trial Optional) | NIDA | Release Date: 12/10/2018 Open Date: 12/10/2018 | 09/09/2021 | R43/R44 | 10 to 30 | Total $7M FY2019 | |
| PAR-19-223 | Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) | NIDA | Release Date: 03/18/2019 Open Date: 09/21/2019 | 10/20/2021 | $up to 300K for up to 5 years | |||
| PAR-19-064 | Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) | NIDA | Release Date: 11/09/2019 Open Date: 01/08/2019 | 11/09/2021 | R21 | $275K for 2 years | ||
| PAR-19-100 | Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional) | NCATS | Release Date: 12/12/2018 Open Date: 02/08/2019 | 11/10/2021 | R21 | Not to exceed $200K | ||
| PAR-19-099 | Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award, (U01 Clinical Trial Optional) | NCATS | Release Date: 12/12/2018 Open Date: 02/08/2019 | 11/10/2021 | U01 | Clinical not to exceed $750K. Non-clinical not to exceed $400K | ||
| PAR-19-278 | Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed) | NIDA | Release Date: 05/08/2019 Open Date: 05/24/2019 | 12/18/2021 | R21/R33 | R21 - Not to exceed $125K/year. R33-Not to exceed $250K | ||
| PAR-19-158 | Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed) | Multi | Release Date: 01/08/2019 Open Date: 01/08/2019 | 01/08/2022 | R01 | Not limited | Translational group | |
| PAR-19-157 | Bioengineering Research Partnerships (U01 Clinical Trial Required) | Multi | Release Date: 01/08/2019 Open Date: 01/08/2019 | 01/08/2022 | U01 | Not limited | Translational group | |
| PAR-19-156 | Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed) | Multi | Release Date: 01/08/2019 Open Date: 01/08/2019 | 01/08/2022 | U01 | Not limited | Translational group | |
| PA-18-946 | Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional) | NINR | Release Date: 10/01/2018 Open Date: 01/16/2018 | 01/08/2022 | R21 | $275K for 2 years | ||
| PA-18-945 | Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional) | NINR | Release Date: 10/01/2018 Open Date: 01/05/2019 | 01/08/2022 | R01 | Not limited | ||
| PA-18-944 | Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional) | NINR | Release Date: 10/01/2018 Open Date: 01/05/2018 | 01/08/2022 | R01 | Not limited | ||
| PA-18-943 | Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional) | NINR | Release Date: 10/01/2018 Open Date: 01/16/2018 | 01/08/2022 | R21 | $275K for 2 years | ||
| NOT-DA-19-066 | Notice of Special Interest (NOSI): Epidemiology of Drug Abuse | NIDA | Release Date: 08/29/2019 Open Date: 10/05/2019 | 01/08/2022 | ||||
| PAR-20-118 | National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional) | NIH | Release Date: 02/25/2020 Open Date: 06/27/2020 | 03/26/2022 | U01 | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. | Application budgets are not limited but need to reflect the actual needs of the proposed project. | |
| PAR-20-119 | National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Substance Use Disorders, or Alcohol Use Disorder (U19 Clinical Trial Optional) | NIH | Release Date: 02/25/2020 Open Date: 06/27/2020 | 03/26/2022 | U19 | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. | Application budgets are not limited but need to reflect the actual needs of the proposed project. | |
| PA-19-201 | Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional) | NIH | Release Date: 02/28/2019 Open Date: 05/16/2019 | 07/08/2022 | R21 | $275K/2 years | ||
| PA-19-200 | Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional) | NIH | Release Date: 02/28/2019 Open Date: 05/05/2019 | 07/08/2022 | R01 | Not limited | ||
| FOA No. | Title | Org | Release/Open Dates | Exp. Date | Activity Code(s) | No. Awards | Amount | Comments |
